Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction

Gabriel Mbalaviele, Gary Anderson, Amy Jones, Pamela De Ciechi, Steve Settle, Steve Mnich, Mark Thiede, Yousef Abu-Amer, Joseph Portanova and Joseph Monahan
Journal of Pharmacology and Experimental Therapeutics June 2006, 317 (3) 1044-1053; DOI: https://doi.org/10.1124/jpet.105.100362
Gabriel Mbalaviele
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Anderson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela De Ciechi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Settle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Mnich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Thiede
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yousef Abu-Amer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Portanova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Monahan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Mitogen-activated protein kinase (MAPK) pathways are implicated in joint destruction in rheumatoid arthritis (RA) by modulating the production and functions of inflammatory cytokines. Although p38 MAPK (p38) participates in signaling cascades leading to osteolysis in arthritis, the mechanisms of its action in this process remain incompletely understood. Here, we found that the osteoclast (Ocl) precursors expressed p38α, but not p38β, p38δ, and p38γ isoforms. Treatment of these cells with receptor activator of nuclear factor (NF)-κB ligand (RANKL) resulted in p38 activation. Importantly, Ocl development induced by RANKL or RANKL and tumor necrosis factor (TNF)-α was blocked with the novel p38 inhibitor 4-(3-(4-chlorophenyl)-5-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)pyrimidine (SC-409). To validate in vitro data, p38 role was further investigated in streptococcal cell wall (SCW)-induced arthritis in rats. We found that SCW-induced joint swelling and bone destruction were attenuated by SC-409. Mechanistically, the data show that SCW-stimulated DNA binding activity of the transcription factor myocyte-enhancing factor 2 C, which is downstream of p38, was inhibited by SC-409. In addition, SC-409 inhibited SCW-stimulated expression of numerous factors, including TNF-α, interleukin-1β, and RANKL. Although c-Jun NH2-terminal kinase and NF-κB pathways were activated in vitro by RANKL and in vivo by SCW, SC-409 had no significant effect on these pathways. In conclusion, our data show that p38 modulates the production and signaling of cytokines, thus providing a mechanism of the bone-sparing effect of SC-409 in rat arthritis. These data present SC-409 as a novel potent p38 inhibitor and suggest that p38-based therapies may be beneficial in preventing bone loss associated with RA.

Footnotes

  • J.P. deceased in July, 2002.

  • doi:10.1124/jpet.105.100362.

  • ABBREVIATIONS: RA, rheumatoid arthritis; TNF, tumor necrosis factor; IL, interleukin; sTNFRII, soluble TNF receptor II; Ocl, osteoclast; NF, nuclear factor; RANK, receptor activator of NF-κB; RANKL, RANK ligand; OPG, osteoprotegerin; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun NH2-terminal kinase; MMP, matrix metalloprotease; SC-409, 4-(3-(4-chlorophenyl)-5-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)pyrimidine; SC-448, 1-(4-(3-(4-chlorophenyl)-4-(pyrimidin-2-yl)-1H-pyrazol-5-yl)piperidin-1-yl)-2-hydroxyethanone; MEF2C, myocyte-enhancing factor 2 C; AP-1, activator protein-1; LPS, lipopolysaccharide; MEM, minimal essential medium; FBS, fetal bovine serum; TRAP, tartrate-resistant acid phosphatase; ELISA, enzyme-linked immunosorbent assay; SCW, streptococcal cell wall; EMSA, electrophoretic mobility shift assay; PCR, polymerase chain reaction; FAM, 6-carboxyfluorescein; TAMRA, 6-carboxy-N,N,N′,N′-tetramethylrhodamine; MGB/NFQ, minor groove binder/nonfluorescent quencher; FP, forward primer; RP, reverse primer; COX, cyclooxygenase; DTT, dithiothreitol; GST, glutathione S-transferase; MITF, microphthalmia transcription factor; M-CSF, macrophage colony-stimulating factor.

    • Received December 20, 2005.
    • Accepted February 22, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 1
1 Apr 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction

Gabriel Mbalaviele, Gary Anderson, Amy Jones, Pamela De Ciechi, Steve Settle, Steve Mnich, Mark Thiede, Yousef Abu-Amer, Joseph Portanova and Joseph Monahan
Journal of Pharmacology and Experimental Therapeutics June 1, 2006, 317 (3) 1044-1053; DOI: https://doi.org/10.1124/jpet.105.100362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction

Gabriel Mbalaviele, Gary Anderson, Amy Jones, Pamela De Ciechi, Steve Settle, Steve Mnich, Mark Thiede, Yousef Abu-Amer, Joseph Portanova and Joseph Monahan
Journal of Pharmacology and Experimental Therapeutics June 1, 2006, 317 (3) 1044-1053; DOI: https://doi.org/10.1124/jpet.105.100362
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PK/PD of Dexamethasone in LPS-Challenged Rats
  • Expression of PAR2 in iKera to Model Atopic Dermatitis
  • Cholesterol Esterification and Acute Lung Injury
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics